The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2020 | LB-100 in low and intermediate risk MDS
Rami Komrokji
• 23 Aug 2020
Rami Komrokji, MD, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, explores the rationale and trial design of a Phase I study evaluating LB-100, a phosphatase inhibitor, in low and intermediate-risk myelodysplastic syndrome (MDS) patients with or without deletion 5q, a common genetic abnormality in MDS. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
